Neurobiology of Brain Disorders is the first book directed primarily at basic scientists to offer a comprehensive overview of neurological and neuropsychiatric disease. This book links basic, translational, and clinical research, covering the genetic, developmental, molecular, and cellular mechanisms underlying all major categories of brain disorders. It offers students, postdoctoral fellows, and researchers in the diverse fields of neuroscience, neurobiology, neurology, and psychiatry the tools they need to obtain a basic background in the major neurological and psychiatric diseases, and to discern connections between basic research and these relevant clinical conditions. This book addresses developmental, autoimmune, central, and peripheral neurodegeneration; infectious diseases; and diseases of higher function. The final chapters deal with broader issues, including some of the ethical concerns raised by neuroscience and a discussion of health disparities. Included in each chapter is coverage of the clinical condition, diagnosis, treatment, underlying mechanisms, relevant basic and translational research, and key unanswered questions. Written and edited by a diverse team of international experts, Neurobiology of Brain Disorders is essential reading for anyone wishing to explore the basic science underlying neurological and neuropsychiatric diseases. Links basic, translational, and clinical research on disorders of the nervous system, creating a format for study that will accelerate disease prevention and treatment Covers a vast array of neurological disorders, including ADHD, Down syndrome, autism, muscular dystrophy, diabetes, TBI, Parkinson, Huntington, Alzheimer, OCD, PTSD, schizophrenia, depression, and pain Illustrated in full color Each chapter provides in-text summary points, special feature boxes, and research questions Provides an up-to-date synthesis of primary source materialGlucocorticoids have short-term effects on the speed of functional recovery in patients with acute attacks of MS and are widely ... they are administered intravenously at high doses during relapse periods of MS and steroid tapering is not suggested. ... In a simplified scenario, approved long-term MS therapy can be grouped into three categories based on their ... to treat MS reduce annual relapse rate, stabilize or decrease the MRI lesion burden, and limit the accumulation of disability.
|Title||:||Neurobiology of Brain Disorders|
|Author||:||Michael J. Zigmond, Joseph T. Coyle, Lewis P. Rowland|
|Publisher||:||Elsevier - 2014-12-03|